US278923A
(en)
*
|
|
1883-06-05 |
|
Newspapee weappee |
EP0238259B1
(en)
|
1986-03-12 |
1993-09-29 |
American Cyanamid Company |
Macrolide compounds
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
EP0512042B1
(en)
|
1990-01-24 |
1998-04-08 |
BUCKLEY, Douglas I. |
Glp-1 analogs useful for diabetes treatment
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
AU685803B2
(en)
|
1993-03-29 |
1998-01-29 |
University Of Cincinnati, The |
Analogs of peptide YY and uses thereof
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
EP0803255A4
(en)
|
1994-06-03 |
1999-06-30 |
Tsumura & Co |
DRUG
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5574010A
(en)
|
1994-11-14 |
1996-11-12 |
The Regents Of The University Of California |
Treatment of pancreatic tumors with peptide YY and analogs thereof
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
US5866536A
(en)
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
BRPI9711437B8
(pt)
|
1996-08-30 |
2021-05-25 |
Novo Nordisk As |
derivados de glp-1
|
ATE366584T1
(de)
|
1996-11-12 |
2007-08-15 |
Novo Nordisk As |
Verwendung von glp-1 peptiden
|
WO1998020885A1
(en)
|
1996-11-13 |
1998-05-22 |
University Of Cincinnati |
Analogs of peptide yy and uses thereof
|
US5773647A
(en)
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
EP0908515A3
(en)
|
1997-09-16 |
2000-04-26 |
Smithkline Beecham Plc |
Pancreatic polypeptide
|
AU2610899A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
JP2002512175A
(ja)
|
1998-02-27 |
2002-04-23 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1類似体の誘導体類
|
AU2610799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
|
WO1999043705A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
US6046167A
(en)
|
1998-03-25 |
2000-04-04 |
University Of Cincinnati |
Peptide YY analogs
|
CA2334298C
(en)
|
1998-06-08 |
2008-01-08 |
Schering Corporation |
Neuropeptide y5 receptor antagonists
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
DE69911975T2
(de)
|
1998-07-31 |
2004-09-09 |
Novo Nordisk A/S |
In-vitro stimulation von beta zellen vermehrung
|
MY155270A
(en)
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
NZ527241A
(en)
|
1998-12-07 |
2004-12-24 |
Sod Conseils Rech Applic |
Analogues of GLP-1
|
EP1149066B1
(en)
|
1999-02-05 |
2005-11-09 |
Emisphere Technologies, Inc. |
Method of preparing alkylated salicylamides
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
JP2002537321A
(ja)
|
1999-02-22 |
2002-11-05 |
エラン コーポレイション ピーエルスィー |
促進剤を含む固体経口剤形
|
WO2000048589A1
(en)
|
1999-02-22 |
2000-08-24 |
Emisphere Holdings, Inc. |
Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
|
EP1175443A1
(en)
|
1999-04-30 |
2002-01-30 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
ATE252601T1
(de)
|
1999-05-17 |
2003-11-15 |
Conjuchem Inc |
Lang wirkende insulinotrope peptide
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
GB9923436D0
(en)
|
1999-10-04 |
1999-12-08 |
American Home Prod |
Pharmaceutical compositions
|
US6793934B1
(en)
|
1999-12-08 |
2004-09-21 |
Shire Laboratories, Inc. |
Solid oral dosage form
|
US7262325B2
(en)
|
2000-06-02 |
2007-08-28 |
Emisphere Technologies, Inc. |
Method of preparing salicylamides
|
US7049283B2
(en)
|
2000-12-06 |
2006-05-23 |
Novartis Ag |
Pharmaceutical compositions for the oral delivery of pharmacologically active agents
|
PL393178A1
(pl)
|
2000-12-07 |
2011-02-14 |
Eli Lilly And Company |
Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulino-niezależną i kompozycja farmaceutyczna do leczenia pacjentów z otyłością
|
US7199217B2
(en)
|
2000-12-13 |
2007-04-03 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
MXPA03005388A
(es)
|
2000-12-14 |
2003-09-25 |
Amylin Pharmaceuticals Inc |
Peptido yy y agonistas de peptido yy para el tratamiento de desordenes metabolicos.
|
US6589938B2
(en)
|
2001-06-29 |
2003-07-08 |
National University Of Singapore |
Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
|
US20030068356A1
(en)
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
DE60228972D1
(de)
|
2001-07-31 |
2008-10-30 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
US7459432B2
(en)
|
2001-09-24 |
2008-12-02 |
Imperial College Innovations Ltd. |
Modification of feeding behavior
|
EP1461031B1
(en)
|
2001-11-29 |
2016-06-29 |
Emisphere Technologies, Inc. |
Formulations for oral administration of cromolyn sodium
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
MXPA04007427A
(es)
|
2002-02-01 |
2004-10-11 |
Pfizer Prod Inc |
Formulaciones de azitromicina granuladas por via seca.
|
EP1478233B1
(en)
|
2002-02-20 |
2016-11-09 |
Emisphere Technologies, Inc. |
Method for administering glp-1 molecules
|
DK1525219T3
(da)
|
2002-07-04 |
2009-09-07 |
Zealand Pharma As |
GLP-1 og fremgangsm der til behandling af diabetes
|
JP2004131398A
(ja)
|
2002-10-08 |
2004-04-30 |
Taihei Chemical Industrial Co Ltd |
錠剤用滑沢剤
|
US7811989B2
(en)
|
2003-01-17 |
2010-10-12 |
Ipsen Pharma S.A.S. |
Peptide YY analogs
|
US20050059605A1
(en)
|
2003-01-31 |
2005-03-17 |
Krishna Peri |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
CN1832959A
(zh)
|
2003-03-19 |
2006-09-13 |
伊莱利利公司 |
聚乙二醇连接的glp-1化合物
|
NZ543274A
(en)
|
2003-05-14 |
2007-12-21 |
Emisphere Tech Inc |
Compositions for delivering peptide YY and PYY agonists
|
US7572581B2
(en)
|
2003-06-30 |
2009-08-11 |
Roche Molecular Systems, Inc. |
2′-terminator nucleotide-related methods and systems
|
BRPI0412458A
(pt)
|
2003-07-11 |
2006-10-17 |
Novartis Ag |
composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
|
WO2005014049A2
(en)
|
2003-08-08 |
2005-02-17 |
Novo Nordisk A/S |
Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
|
CN101380476A
(zh)
|
2003-09-19 |
2009-03-11 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
CA2539253A1
(en)
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
WO2005028516A2
(en)
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
KR101243648B1
(ko)
|
2003-11-20 |
2013-03-14 |
노보 노르디스크 에이/에스 |
제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
|
BRPI0417717A
(pt)
|
2003-12-18 |
2007-04-03 |
Novo Nordisk As |
composto, composição farmacêutica, e, uso de um composto
|
EP1696962A2
(en)
|
2003-12-18 |
2006-09-06 |
Novo Nordisk A/S |
Novel glp-1 analogues linked to albumin-like agents
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
EP2335715A3
(en)
|
2004-02-11 |
2013-12-18 |
Amylin Pharmaceuticals, LLC |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
WO2005077072A2
(en)
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
AU2005224026A1
(en)
|
2004-03-17 |
2005-09-29 |
7Tm Pharma A/S |
Y2 selective receptor agonists for therapeutic interventions
|
US20090186811A1
(en)
|
2004-03-17 |
2009-07-23 |
Thue Schwartz |
Y2 Selective Receptor Agonists for Therapeutic Interventions
|
WO2005089790A2
(en)
|
2004-03-17 |
2005-09-29 |
7Tm Pharma A/S |
Y2/y4 selective receptor agonists for therapeutic interventions
|
JP2007529463A
(ja)
|
2004-03-17 |
2007-10-25 |
7ティーエム ファーマ エイ/エス |
治療的介入のためのy4選択性レセプターアゴニスト
|
WO2005099672A1
(en)
|
2004-04-13 |
2005-10-27 |
Ranbaxy Laboratories Limited |
A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
|
CA2897225C
(en)
|
2004-05-06 |
2017-12-05 |
Emisphere Technologies, Inc. |
Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
|
NZ550894A
(en)
|
2004-05-06 |
2011-02-25 |
Emisphere Tech Inc |
Solid dosage form of wetted heparin
|
WO2005112633A2
(en)
|
2004-05-14 |
2005-12-01 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
WO2005121090A1
(en)
|
2004-06-02 |
2005-12-22 |
Abbott Laboratories |
Substituted piperidines that have antiangiogenic activity
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
CN101010339B
(zh)
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
JP2008507477A
(ja)
|
2004-07-08 |
2008-03-13 |
ノボ ノルディスク アクティーゼルスカブ |
ポリペプチド延長タグ
|
CA2573512C
(en)
|
2004-07-12 |
2014-09-23 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide yy and pyy agonists
|
US7994119B2
(en)
|
2004-07-19 |
2011-08-09 |
University Of Cincinnati |
Compounds for control of appetite
|
US20060078622A1
(en)
|
2004-08-13 |
2006-04-13 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
WO2006049681A2
(en)
|
2004-08-30 |
2006-05-11 |
Bayer Pharmaceuticals Corporation |
Selective neuropeptide y2 receptor agonists
|
JP2008515856A
(ja)
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性glp−1化合物
|
JP5107713B2
(ja)
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー/エス |
遅延性のエキセンディン−4化合物
|
US7410949B2
(en)
|
2005-01-18 |
2008-08-12 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
|
ES2540929T3
(es)
|
2005-02-01 |
2015-07-14 |
Emisphere Technologies, Inc. |
Sistema de administración de retención gástrica y liberación controlada
|
ES2438145T3
(es)
|
2005-02-02 |
2014-01-16 |
Novo Nordisk A/S |
Nuevos derivados de insulina
|
WO2006096515A2
(en)
|
2005-03-04 |
2006-09-14 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins
|
GB0504857D0
(en)
|
2005-03-09 |
2005-04-13 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
ES2484796T3
(es)
|
2005-03-18 |
2014-08-12 |
Novo Nordisk A/S |
Compuestos de GLP-1 extendidos
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
JP2008533104A
(ja)
|
2005-03-18 |
2008-08-21 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1受容体の二量体ペプチドアゴニスト
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
EP1863449A2
(en)
|
2005-03-28 |
2007-12-12 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
PE20061448A1
(es)
|
2005-05-26 |
2006-12-17 |
Bristol Myers Squibb Co |
Compuestos polipeptidos como moduladores del peptido 1 similar al glucagon humano
|
WO2007008778A2
(en)
|
2005-07-11 |
2007-01-18 |
Nastech Pharmaceutical Company Inc. |
Formulations for enhanced mucosal delivery of pyy
|
US8975227B2
(en)
|
2005-07-15 |
2015-03-10 |
Emisphere Technologies, Inc. |
Intraoral dosage forms of glucagon
|
US20090203581A1
(en)
|
2005-07-18 |
2009-08-13 |
Novo Nordisk A/S |
Novel Peptides for Use in the Treatment of Obesity
|
JP5693817B2
(ja)
|
2005-08-19 |
2015-04-01 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
糖尿病の治療法および体重の減少法
|
US20070049557A1
(en)
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
US8022035B2
(en)
|
2005-09-21 |
2011-09-20 |
7Tm Pharma A/S |
Y4 selective receptor agonists for therapeutic interventions
|
EA200800875A1
(ru)
|
2005-09-21 |
2008-08-29 |
7ТиЭм ФАРМА А/С |
Рецепторные агонисты, селективные к y2 рецептору, для терапевтического воздействия
|
WO2007061434A2
(en)
|
2005-11-10 |
2007-05-31 |
Nastech Pharmaceutical Company Inc. |
A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
|
CN101309674A
(zh)
|
2005-11-17 |
2008-11-19 |
诺瓦提斯公司 |
药物组合物
|
KR101059602B1
(ko)
|
2005-12-07 |
2011-08-25 |
에프. 호프만-라 로슈 아게 |
신경펩타이드 2 수용체 작용물질
|
BRPI0620571A2
(pt)
|
2005-12-08 |
2011-11-22 |
Nastech Pharm Co |
formulação farmacêutica aquosa, forma de dosagem de exendina, solução aquosa, uso de uma formulação farmacêutica, e uso de uma formulação farmacêutica aquosa
|
EP1963343A1
(en)
|
2005-12-14 |
2008-09-03 |
Novo Nordisk A/S |
Polypeptide protracting tags
|
US20070197445A1
(en)
|
2006-01-18 |
2007-08-23 |
University Of Cincinnati |
Compounds for control of appetite
|
JP5412273B2
(ja)
|
2006-03-21 |
2014-02-12 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
ペプチド−ぺプチダーゼ阻害剤及びその使用
|
BRPI0710503A2
(pt)
|
2006-04-07 |
2011-08-16 |
Merrion Res Iii Ltd |
uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
|
US8927015B2
(en)
|
2006-04-12 |
2015-01-06 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
MX2008014061A
(es)
|
2006-05-09 |
2008-11-14 |
Novo Nordisk As |
Derivado de insulina.
|
US20070292512A1
(en)
|
2006-06-09 |
2007-12-20 |
Merrion Research Ii Limited |
Solid Oral Dosage Form Containing an Enhancer
|
JP5475443B2
(ja)
|
2006-06-28 |
2014-04-16 |
エミスフェアー・テクノロジーズ・インク |
硝酸ガリウム製剤
|
GB0613196D0
(en)
|
2006-07-03 |
2006-08-09 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
ES2296529B1
(es)
|
2006-08-07 |
2009-04-01 |
Laboratorios Farmaceuticos Rovi, S.A. |
Composicion farmaceutica con promotores de absorcion.
|
US20090318353A1
(en)
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
CN101506147B
(zh)
|
2006-09-07 |
2012-03-21 |
霍夫曼-拉罗奇有限公司 |
用于制备snac(n-(8-[2-羟基苯甲酰基]-氨基)辛酸钠)的方法
|
TWI430806B
(zh)
|
2006-09-13 |
2014-03-21 |
Smithkline Beecham Corp |
用於投與長效降血糖藥劑之方法
|
PE20080845A1
(es)
|
2006-09-22 |
2008-08-13 |
Novartis Ag |
Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
US20100069410A1
(en)
|
2006-12-01 |
2010-03-18 |
Emisphere Technologies Inc. |
acyclovir formulations
|
US20090099074A1
(en)
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
US20100022446A1
(en)
|
2007-01-18 |
2010-01-28 |
Novo Nordisk A/S |
Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
|
JP2010516652A
(ja)
|
2007-01-18 |
2010-05-20 |
ノボ・ノルデイスク・エー/エス |
肥満の治療に使用される新規ペプチド
|
CA2679782C
(en)
|
2007-03-02 |
2015-02-17 |
Novartis Ag |
Oral administration of a calcitonin
|
GB0708226D0
(en)
|
2007-04-27 |
2007-06-06 |
7Tm Pharma As |
Y-receptor agonists
|
EP2171080A4
(en)
|
2007-06-12 |
2010-10-27 |
Glaxosmithkline Llc |
METHODS OF PROTEIN DETECTION IN PLASMA
|
EP2167535A2
(en)
|
2007-07-09 |
2010-03-31 |
Imperial Innovations Limited |
Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
|
EP2182956A2
(en)
|
2007-08-29 |
2010-05-12 |
The Regents of the University of California |
Salicylanilide modified peptides for use as oral therapeutics
|
WO2009030738A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
ES2550363T3
(es)
|
2007-09-05 |
2015-11-06 |
Novo Nordisk A/S |
Derivados truncados de GLP-1 y su uso terapéutico
|
ES2532116T3
(es)
|
2007-09-05 |
2015-03-24 |
Novo Nordisk A/S |
Péptidos derivados con A-B-C-D y sus usos terapéuticos
|
AU2008303922A1
(en)
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Use of the peptide His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe alone or in combination with the peptide Gly-Ard-Gly-Asp-Asn-Pro-OH as a therapeutic agent
|
WO2009042922A2
(en)
|
2007-09-27 |
2009-04-02 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of making and using same
|
JP5868594B2
(ja)
|
2007-10-16 |
2016-02-24 |
バイオコン・リミテッドBiocon Limited |
経口投与可能な固形医薬組成物及びそのプロセス
|
PL2215047T3
(pl)
|
2007-11-02 |
2014-05-30 |
Emisphere Tech Inc |
Sposób leczenia niedoborów witaminy b12
|
US20090124639A1
(en)
|
2007-11-06 |
2009-05-14 |
Emisphere Technologies Inc. |
valacyclovir formulations
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
BRPI0912615A2
(pt)
|
2008-05-16 |
2016-01-26 |
Novo Nordisk As |
agonistas de receptor y2 e/ou y4 de longa ação
|
ES2823233T3
(es)
|
2008-08-18 |
2021-05-06 |
Entera Bio Ltd |
Métodos y composiciones para la administración oral de proteínas
|
EP2340049B1
(en)
|
2008-09-12 |
2015-11-11 |
Novo Nordisk A/S |
Method of acylating a peptide or protein
|
US8299023B2
(en)
|
2008-09-17 |
2012-10-30 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists
|
GB0817067D0
(en)
|
2008-09-18 |
2008-10-22 |
7Tm Pharma As |
Intestinal treatment
|
ES2445540T3
(es)
|
2008-10-15 |
2014-03-03 |
Bayer Cropscience Ag |
Uso de ditiina-tetracarboximidas para combatir hongos fitopatógenos
|
KR20110097807A
(ko)
|
2008-11-05 |
2011-08-31 |
에프. 호프만-라 로슈 아게 |
뉴로펩티드-2-수용체(y-2r) 작용제 및 이의 용도
|
CN101463081B
(zh)
|
2009-01-12 |
2012-07-04 |
华东师范大学 |
一种glp-1衍生物
|
JP2012517977A
(ja)
|
2009-02-13 |
2012-08-09 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dpp−4阻害剤(リナグリプチン)を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
|
JP5584236B2
(ja)
|
2009-02-20 |
2014-09-03 |
イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ |
神経ペプチドy受容体結合化合物を有する細胞毒性コンジュゲート
|
AR077956A1
(es)
|
2009-09-14 |
2011-10-05 |
Bayer Cropscience Ag |
Combinaciones de compuestos activos
|
JP2013505221A
(ja)
|
2009-09-18 |
2013-02-14 |
ノヴォ ノルディスク アー/エス |
長時間作用性y2受容体アゴニスト
|
CA2776302A1
(en)
|
2009-10-13 |
2011-04-21 |
F. Hoffmann-La Roche Ag |
Neuropeptide-2 receptor (y-2r) agonists
|
JP2013510829A
(ja)
|
2009-11-13 |
2013-03-28 |
ノヴォ ノルディスク アー/エス |
長時間作用型y2受容体アゴニスト
|
EP2513141B1
(en)
|
2009-12-16 |
2017-03-01 |
Novo Nordisk A/S |
Glp-1 analogues and derivatives
|
WO2011084618A2
(en)
|
2009-12-16 |
2011-07-14 |
Nod Pharmaceuticals, Inc. |
Compositions and methods for oral drug delivery
|
US20110182985A1
(en)
|
2010-01-28 |
2011-07-28 |
Coughlan David C |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
|
WO2011109787A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Methods of administering insulinotropic peptides
|
WO2011116139A2
(en)
|
2010-03-16 |
2011-09-22 |
Chiasma Inc. |
Improved pharmaceutical compositions and methods of delivery
|
US9040660B2
(en)
|
2010-04-20 |
2015-05-26 |
Novo Nordisk A/S |
Long-acting gastrin derivatives
|
MX2012012383A
(es)
|
2010-04-30 |
2012-11-30 |
Sanwa Kagaku Kenkyusho Co |
Peptido para mejorar la bioestabilidad de una sustancia bioactica y sustancia bioactiva que tiene bioestabilidad mejorada.
|
CN102946875A
(zh)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
组合疗法
|
DE202010015867U1
(de)
|
2010-11-25 |
2011-05-05 |
Buchhalter, Thomas |
Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
|
DK3326620T3
(da)
*
|
2010-12-16 |
2020-05-25 |
Novo Nordisk As |
Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
|
GB201101459D0
(en)
|
2011-01-27 |
2011-03-16 |
Imp Innovations Ltd |
Novel compounds and thier effects on fedding behaviour
|
KR101972836B1
(ko)
|
2011-04-12 |
2019-04-29 |
노보 노르디스크 에이/에스 |
이중 아실화된 glp-1 유도체
|
WO2013009545A1
(en)
|
2011-07-08 |
2013-01-17 |
Amylin Pharmaceuticals, Inc. |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
DE102012102301B4
(de)
|
2012-03-19 |
2021-06-17 |
OSRAM Opto Semiconductors Gesellschaft mit beschränkter Haftung |
Optoelektronischer Halbleiterchip und Scheinwerfer mit einem solchen Halbleiterchip
|
US10335369B2
(en)
*
|
2012-03-22 |
2019-07-02 |
Novo Nordisk A/S |
Compositions comprising a delivery agent and preparation thereof
|
DK2827845T3
(en)
|
2012-03-22 |
2019-04-01 |
Novo Nordisk As |
COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
|
HUE062740T2
(hu)
*
|
2012-03-22 |
2023-12-28 |
Novo Nordisk As |
GLP-1 peptidek készítményei és elõállításuk
|
US20150141336A1
(en)
|
2012-05-29 |
2015-05-21 |
Novo Nordisk A/S |
Pancreatic Peptide Compounds and Use
|
ES2871328T3
(es)
|
2012-06-20 |
2021-10-28 |
Novo Nordisk As |
Formulación de comprimido que comprende un péptido y un agente de suministro
|
SI2866825T1
(sl)
|
2012-07-01 |
2020-07-31 |
Novo Nordisk A/S |
Uporaba dolgo delujočih peptidov GLP-1
|
CN105263957A
(zh)
|
2013-05-02 |
2016-01-20 |
葛兰素史克知识产权开发有限公司 |
治疗肽
|
EP2991671B1
(en)
|
2013-05-02 |
2018-08-15 |
Novo Nordisk A/S |
Oral dosing of glp-1 compounds
|
JP6629198B2
(ja)
|
2013-11-15 |
2020-01-15 |
ノヴォ ノルディスク アー/エス |
35位にβ−ホモアルギニン置換を有するHPYY(1−36)
|
TWI661835B
(zh)
|
2013-11-15 |
2019-06-11 |
丹麥商諾佛 儂迪克股份有限公司 |
選擇性pyy化合物及其用途
|
WO2015155151A1
(en)
|
2014-04-07 |
2015-10-15 |
Novo Nordisk A/S |
Double-acylated glp-1 compounds
|
CN107205949A
(zh)
*
|
2015-01-29 |
2017-09-26 |
诺和诺德股份有限公司 |
包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物
|
US20180050096A1
(en)
*
|
2015-02-09 |
2018-02-22 |
Entera Bio Ltd. |
Treatment of hypoparathyroidism
|
AU2016275735B2
(en)
|
2015-06-12 |
2020-02-06 |
Novo Nordisk A/S |
Selective PYY compounds and uses thereof
|
WO2017060500A1
(en)
*
|
2015-10-07 |
2017-04-13 |
Cyprumed Gmbh |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
AR112015A1
(es)
|
2017-06-09 |
2019-09-11 |
Novo Nordisk As |
Composiciones sólidas para administración oral
|
AR112480A1
(es)
|
2017-08-24 |
2019-10-30 |
Novo Nordisk As |
Composiciones de glp-1 y sus usos
|
CN111683676B
(zh)
|
2018-02-02 |
2024-06-18 |
诺和诺德股份有限公司 |
包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
|
JP2022545156A
(ja)
*
|
2019-08-07 |
2022-10-26 |
ノヴォ ノルディスク アー/エス |
Glp-1作動薬と、sglt2阻害剤と、n-(8-(2-ヒドロキシベンゾイル)アミノ)カプリル酸の塩とを含む固形組成物
|